DNA FINANCIAL STATEMENTS

Ginkgo Bioworks Holdings — balance sheet, income statement and cash flow trends

DNAGinkgo Bioworks Holdings

🇺🇸 USA · NYSE · Healthcare · Biotechnology

Value it Duel

Income Statement

Quarterly progression — trailing-twelve-month values

RevenueNet Income

Profit Funnel

Q1 2026 · TTM

Percentages are relative to revenue.

Key Figures

YoY change

Revenue141.3 M $-40.5%

Gross Profit105.9 M $-44.8%

Operating Income-297.7 M $—

EBITDA-210.9 M $—

Net Income-304.4 M $—

Peer Comparison· Biotechnology

Company	Rev. Growth	Gross Margin	EBITDA Margin	Net Margin
DNA	-40.5%	75.0%	-149.2%	-215.4%
MSB	410.4%	-32.0%	-76.6%	-115.3%
TLX	56.3%	50.8%	3.0%	-0.9%
RTALB	24.0%	35.1%	9.0%	136.3%
CSL	4.8%	48.6%	32.8%	9.2%
Industry median	5.1%	84.0%	-105.8%	-125.7%

Company	Rev. Growth	Gross Margin	EBITDA Margin	Net Margin
DNA	-40.5%	75.0%	-149.2%	-215.4%
OMER	—	—	—	—
MDXG	10.5%	81.0%	14.7%	7.9%
ZURA	-100.0%	—	—	—
PRME	-90.3%	-1,082.7%	-4,732.2%	-4,917.6%
RGNX	-44.0%	-0.1%	-261.2%	-330.2%
Industry median	5.1%	84.0%	-105.8%	-125.7%

Balance Sheet

Quarterly period-end values

Total AssetsTotal LiabilitiesEquity

Capital Structure

Q1 2026

Equity443.2 M $43%
Current Liabilities79.6 M $8%
Long-term Liabilities510.3 M $49%

Key Figures

YoY change

Total Assets1 B $-20.1%

Total Liabilities589.9 M $-8.7%

Total Equity443.2 M $-31.6%

Cash & ST Investments373.5 M $-27.8%

Total Debt410.7 M $-5.5%

Net Debt266.8 M $+118.5%

Peer Comparison· Biotechnology

Company	Current Ratio	Debt/Equity	NetDebt/EBITDA	Equity/Assets
DNA	5.15	92.7%	-0.18	42.9%
MSB	—	—	—	—
TLX	1.43	112.3%	13.13	35.1%
RTALB	1.21	1.2%	0.90	84.9%
CSL	2.57	67.4%	2.22	49.2%
Industry median	5.90	10.9%	1.15	70.0%

Company	Current Ratio	Debt/Equity	NetDebt/EBITDA	Equity/Assets
DNA	5.15	92.7%	-0.18	42.9%
OMER	3.03	-490.5%	—	-22.1%
MDXG	5.39	7.2%	-2.48	78.7%
ZURA	19.33	—	—	94.9%
PRME	3.80	149.3%	0.11	26.0%
RGNX	2.62	337.1%	0.35	6.2%
Industry median	5.90	10.9%	1.15	70.0%

Cash Flow Statement

Quarterly progression — trailing-twelve-month values

Operating Cash FlowCapital ExpendituresFree Cash Flow

Cash Flow Bridge

Q1 2026 · TTM

Key Figures

YoY change

Operating Cash Flow-166 M $—

Capital Expenditures25 M $-60.7%

Free Cash Flow-183.3 M $—

Dividends Paid——

Peer Comparison· Biotechnology

Company	CF Margin	FCF Margin	CapEx Ratio	CF/Net Income
DNA	-117.5%	-129.7%	17.7%	54.5%
MSB	-87.7%	-90.0%	2.3%	76.1%
TLX	-2.2%	-6.3%	4.1%	243.1%
RTALB	58.5%	88.6%	10.8%	42.9%
CSL	24.0%	20.3%	3.7%	261.5%
Industry median	-88.0%	-90.9%	1.9%	81.5%

Company	CF Margin	FCF Margin	CapEx Ratio	CF/Net Income
DNA	-117.5%	-129.7%	17.7%	54.5%
OMER	—	—	—	—
MDXG	18.1%	16.8%	1.3%	229.9%
ZURA	—	—	—	96.3%
PRME	-3,877.5%	-3,935.1%	57.6%	78.8%
RGNX	-266.2%	-269.2%	3.0%	80.6%
Industry median	-88.0%	-90.9%	1.9%	81.5%

Amounts are in the company’s reporting currency. Peer comparison tables use ratio-based metrics so currency differences do not distort the picture.

Go deeper on DNA

Run a DCF valuation

Full DCF model with editable assumptions

Start a head-to-head duel

Compare two stocks metric by metric

Filter in the stock screener

Build your own universe with 400+ metrics

Data on this page refreshes once per day. Price data as of Jul 2, 26. This content is for informational purposes only and is not investment advice.